AR052033A1 - Composicion farmaceutica que comprende inhibidor de topoisomerasa i - Google Patents

Composicion farmaceutica que comprende inhibidor de topoisomerasa i

Info

Publication number
AR052033A1
AR052033A1 ARP050104840A ARP050104840A AR052033A1 AR 052033 A1 AR052033 A1 AR 052033A1 AR P050104840 A ARP050104840 A AR P050104840A AR P050104840 A ARP050104840 A AR P050104840A AR 052033 A1 AR052033 A1 AR 052033A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
camptothecin
spontaneously dispersible
active agent
topoisomerasa
Prior art date
Application number
ARP050104840A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35691476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR052033A1 publication Critical patent/AR052033A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas en donde el agente activo es un inhibidor de topoisomerasa I, en particular un derivado de camptotecina, que es util para el tratamiento y la prevencion de enfermedades proliferativas, incluyendo cáncer. Reivindicacion 1: Una composicion farmacéutica espontáneamente dispersable, la cual comprende 7-terbutoxi-imino-metil-camptotecina. Reivindicacion 2: Una composicion farmacéutica espontáneamente dispersable, la cual comprende un derivado de camptotecina y un medio de vehículo que comprende un componente lipofílico, un tensioactivo, y un componente hidrofílico. Reivindicacion 32:Un proceso para la preparacion de una micro-emulsion que contiene 7-terbutoxi-imino-metil-camptotecina como agente activo, cuyo proceso comprende: (i) poner en mezcla íntima el agente activo y un vehículo que comprende: (1) un componente lipofílico, (2) un tensioactivo, y (3) un componente hidrofílico, para formar una composicion farmacéutica espontáneamente dispersable; y (ii) diluir l composicion farmacéutica espontáneamente dispersable en un medio acuoso, para formar la micro-emulsion.
ARP050104840A 2004-11-19 2005-11-17 Composicion farmaceutica que comprende inhibidor de topoisomerasa i AR052033A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62975704P 2004-11-19 2004-11-19

Publications (1)

Publication Number Publication Date
AR052033A1 true AR052033A1 (es) 2007-02-28

Family

ID=35691476

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104840A AR052033A1 (es) 2004-11-19 2005-11-17 Composicion farmaceutica que comprende inhibidor de topoisomerasa i

Country Status (28)

Country Link
US (1) US8518961B2 (es)
EP (1) EP1814520B1 (es)
JP (1) JP4982378B2 (es)
KR (1) KR101283840B1 (es)
CN (1) CN101056619A (es)
AR (1) AR052033A1 (es)
AU (1) AU2005306018B2 (es)
BR (1) BRPI0518448A2 (es)
CA (1) CA2584343C (es)
DK (1) DK1814520T3 (es)
ES (1) ES2572133T3 (es)
GT (1) GT200500310A (es)
HR (1) HRP20160446T1 (es)
HU (1) HUE027135T2 (es)
IL (1) IL182703A (es)
MA (1) MA29076B1 (es)
MX (1) MX2007005897A (es)
MY (1) MY148647A (es)
NO (1) NO342592B1 (es)
NZ (1) NZ554551A (es)
PE (1) PE20061077A1 (es)
PL (1) PL1814520T3 (es)
RU (3) RU2007122470A (es)
SI (1) SI1814520T1 (es)
TN (1) TNSN07193A1 (es)
TW (1) TWI368521B (es)
WO (1) WO2006053755A1 (es)
ZA (1) ZA200703148B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
PE20070232A1 (es) * 2005-08-10 2007-04-09 Novartis Ag Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina
TW200824686A (en) * 2006-10-31 2008-06-16 Wyeth Corp Formulations of phospholipase enzyme inhibitors
US20100070052A1 (en) * 2008-08-19 2010-03-18 Robb Fujioka System and method for providing applications and peripherals to a fixed price component-based computing platform
CN103313697B (zh) 2010-06-29 2016-06-01 维瑞斯特姆股份有限公司 激酶抑制剂的口服制剂
AU2011280031B2 (en) 2010-06-30 2015-09-10 Verastem, Inc. Synthesis and use of Kinase inhibitors
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
NZ776354A (en) 2018-12-19 2023-03-31 Corcept Therapeutics Inc Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2024042523A1 (en) * 2022-08-24 2024-02-29 Lyotropic Delivery Systems Ltd. Oral delivery of active compounds for treating glycogen storage diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE69823663T2 (de) * 1997-07-29 2005-05-19 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierbare formulierung enthaltend lipophile verbindungen
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
AU3843999A (en) 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
PT1044977E (pt) * 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
KR20070058028A (ko) * 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
CN1592607A (zh) 2001-10-15 2005-03-09 克里蒂泰克公司 水溶性差药物的组合物、其给药方法和治疗方法
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) * 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
DE602004027936D1 (de) * 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc Tocopherolmodifizierte therapeutische arzneimittelverbindung
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
MXPA06006710A (es) 2003-12-17 2006-08-31 Bionumerik Pharmaceuticals Inc Formulaciones farmaceuticas de camptotecinas y proceso para su elaboracion.
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
RU2620331C2 (ru) 2017-05-24
RU2015131700A (ru) 2017-02-02
GT200500310A (es) 2006-06-19
MA29076B1 (fr) 2007-12-03
HRP20160446T1 (hr) 2016-05-20
TNSN07193A1 (en) 2008-11-21
TW200631606A (en) 2006-09-16
AU2005306018A1 (en) 2006-05-26
RU2007122470A (ru) 2008-12-27
NO20072258L (no) 2007-08-10
JP4982378B2 (ja) 2012-07-25
HUE027135T2 (en) 2016-08-29
MY148647A (en) 2013-05-15
IL182703A (en) 2015-11-30
AU2005306018B2 (en) 2009-12-17
EP1814520A1 (en) 2007-08-08
PL1814520T3 (pl) 2016-08-31
CA2584343C (en) 2013-09-24
US8518961B2 (en) 2013-08-27
IL182703A0 (en) 2007-09-20
DK1814520T3 (en) 2016-05-30
US20080125450A1 (en) 2008-05-29
EP1814520B1 (en) 2016-04-13
NZ554551A (en) 2010-01-29
KR101283840B1 (ko) 2013-07-15
KR20070084357A (ko) 2007-08-24
ES2572133T3 (es) 2016-05-30
TWI368521B (en) 2012-07-21
JP2008520606A (ja) 2008-06-19
CA2584343A1 (en) 2006-05-26
WO2006053755A1 (en) 2006-05-26
BRPI0518448A2 (pt) 2008-11-18
ZA200703148B (en) 2008-09-25
CN101056619A (zh) 2007-10-17
PE20061077A1 (es) 2006-11-13
SI1814520T1 (sl) 2016-06-30
NO342592B1 (no) 2018-06-18
MX2007005897A (es) 2007-06-19
RU2012120388A (ru) 2013-11-27

Similar Documents

Publication Publication Date Title
AR052033A1 (es) Composicion farmaceutica que comprende inhibidor de topoisomerasa i
CL2007003730A1 (es) Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.
HRP20200450T1 (hr) Topikalne farmaceutske formulacije koje sadrže nisku koncentraciju benzoil peroksida u suspenziji u vodi i organskog otapala topivog u vodi
BRPI0510684A (pt) composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
WO2006108405A3 (de) Nanopartikel-wirkstoff-konjugate
WO2009102467A3 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
ECSP10010589A (es) Farmaco contra el cancer de higado
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
ECSP11010833A (es) Procedimiento para controlar la degradación de un ingrediente activo químico agrícola
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
CL2014000592A1 (es) Composicion oftalmica de administracion topica que comprende povidona-yodo, esteroide, anestesico, reforzador de la penetracion, preservativo antimicrobiano, cosolvente/surfactante y agente de aumento de la viscosidad; y metodo de tratamiento y/o profilaxis de un trastorno oftalmico o una infeccion por microorganismos en el ojo.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
PE20041065A1 (es) Composiciones farmaceuticas que comprenden ester de testosterona y aceite de ricino
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
TW200718360A (en) Useful high load concentrate composition for control of ecto-and endo-parasites
EA200900572A1 (ru) Мицеллярные наночастицы с химическими субстанциями
TW200724132A (en) Versatile high load concentrate compositions for control of ecto-parasites
AR051664A1 (es) Agente contra la demodicosis
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
AR067751A1 (es) Composicion veterinaria topica, proceso para la preparacion de una composicion y metodo para el tratamiento de infeccion endoparasitaria o infestacion en un animal homeotermico
EA200701542A1 (ru) Антигельминтная композиция
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Legal Events

Date Code Title Description
FB Suspension of granting procedure